Pharmacoeconomic review report. Lurasidone (Latuda - Sunovion Pharmaceuticals Inc.) indication: schizophrenia
CADTH
Record ID 32014000813
English
Authors' recommendations:
At the submitted price of XXXXXX, lurasidone (XXXXXX per year) is less expensive than aripiprazole ($1,509 to $1,746 per year) and ziprasidone ($1,448 per year). Therefore, lurasidone would generate modest cost savings for public plans if it were used instead of aripiprazole or ziprasidone. By contrast, lurasidone is more expensive than quetiapine ($352 to $705) and risperidone ($443 to $665), regardless of dose. Therefore, lurasidone would incur additional costs to public plans if it were used instead of quetiapine or risperidone. Whether lurasidone is more or less expensive than other AAPs (olanzapine, risperidone ODT, quetiapine XR, paliperidone) depends on the dose considered and prices within individual public plans.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0331_Latuda_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Thiazoles
- Isoindoles
- Schizophrenia
- Antipsychotic Agents
- Lurasidone Hydrochloride
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.